{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:28:50Z","timestamp":1790224130651,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006126","name":"Hospital for Sick Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000262","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","award":["CD-CCM-0224-0873-HSC"],"award-info":[{"award-number":["CD-CCM-0224-0873-HSC"]}],"id":[{"id":"10.13039\/501100000262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcjo.2026.01.016","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:35:43Z","timestamp":1772195743000},"page":"685-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene therapy outcomes in young patients with RPE65-retinal degeneration"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-7725","authenticated-orcid":false,"given":"Kirk A.J.","family":"Stephenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar K.","family":"Alsalamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8311-8508","authenticated-orcid":false,"given":"Anupreet","family":"Tumber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth D.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4644-3339","authenticated-orcid":false,"given":"Brian G.","family":"Ballios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-1766","authenticated-orcid":false,"given":"Erika","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoy","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4143-9311","authenticated-orcid":false,"given":"Elise","family":"H\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.01.016_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjo.2020.10.019","article-title":"Treatments for inherited retinal degenerations are coming to Canada: brief update on a new standard of care for inherited retinal degenerations","volume":"56","author":"Heon","year":"2021","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0002","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.preteyeres.2010.04.002","article-title":"Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy","volume":"29","author":"Cideciyan","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0003","first-page":"4293","article-title":"Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration","volume":"41","author":"Thompson","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2018.09.024","article-title":"The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene","volume":"199","author":"Chung","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0005","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/jamaophthalmol.2024.3641","article-title":"Incidence and risk of depressive disorder in patients with retinitis pigmentosa","volume":"142","author":"Kim","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0006","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/OPTH.S241928","article-title":"The impact of inherited retinal diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a cost-of-illness perspective","volume":"14","author":"Galvin","year":"2020","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0007","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.2147\/OPTH.S313719","article-title":"The impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective","volume":"15","author":"Gong","year":"2021","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0008","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0009","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","article-title":"Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis","volume":"260","author":"Deng","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/biomedicines11010103","article-title":"Gene therapy with voretigene neparvovec improves vision and partially restores electrophysiological function in pre-school children with Leber congenital amaurosis","volume":"11","author":"Gerhardt","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22180-6","article-title":"Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy","volume":"12","author":"Testa","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0012","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based PERCEIVE Study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0013","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0014","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.3390\/jcm11164717","article-title":"Subretinal injection techniques for retinal disease: a review","volume":"11","author":"Irigoyen","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjo.2024.12.013","article-title":"Blindness\" is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 Patients","volume":"60","author":"Parameswarappa","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0016","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jcjo.2024.12.006","article-title":"Insights into the effects of subretinal voretigene neparvovec-rzyl in RPE65-associated Leber congenital amaurosis","volume":"60","author":"Tayyib","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0018","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1167\/iovs.02-1100","article-title":"How sensitive to clinical change are ETDRS logMAR visual acuity measurements?","volume":"44","author":"Rosser","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0019","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-4614-3209-8_17","article-title":"Digital quantification of Goldmann visual fields (GVFs) as a means for genotype-phenotype comparisons and detection of progression in retinal degenerations","volume":"801","author":"Zahid","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.oret.2023.08.017","article-title":"Classification and growth rate of chorioretinal atrophy after voretigene neparvovec-rzyl for RPE65-mediated retinal degeneration","volume":"8","author":"Bommakanti","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0022","article-title":"Normative data for retinal-layer thickness maps generated by spectral-domain OCT in a white population","volume":"2","author":"Invernizzi","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0023","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s00417-024-06448-3","article-title":"Hyalocytes-guardians of the vitreoretinal interface","volume":"262","author":"Lange","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0024","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/17469899.2022.2100762","article-title":"Hyalocyte origin, structure, and imaging","volume":"17","author":"Wieghofer","year":"2022","journal-title":"Expert Rev Ophthalmol"},{"issue":"2","key":"10.1016\/j.jcjo.2026.01.016_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/bjo-2024-326221","article-title":"12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy","volume":"109","author":"Daruich","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101354","article-title":"Gene therapy-associated uveitis (GTAU): understanding and mitigating the adverse immune response in retinal gene therapy","volume":"106","author":"Purdy","year":"2025","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0027","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0028","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0161-6420(97)30052-9","article-title":"Ocular-hypertensive response to topical steroids in children","volume":"104","author":"Kwok","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0029","first-page":"1274","article-title":"Intraocular pressure response to topical corticosteroids","volume":"24","author":"Armaly","year":"1965","journal-title":"Fed Proc"},{"key":"10.1016\/j.jcjo.2026.01.016_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049976","article-title":"Two-step versus 1-step subretinal injection to compare subretinal drug delivery: a randomised study protocol","volume":"11","author":"Simunovic","year":"2021","journal-title":"BMJ Open"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:37:18Z","timestamp":1781253438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418226000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0008418226000165"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.01.016","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy outcomes in young patients with RPE65-retinal degeneration","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}